Pharmacological Treatment of Presbyopia Using Pilocarpine 1.25% Eye Drops
Purpose: To assess the efficiency and safety of pilocarpine eye drop 1.25% analogue (IRPilo) in comparison with its original brand-name drug (Vuity). Methods: In this non-randomized comparative study, 75 patients with presbyopia aged 40 to 60 years were enrolled. The right eyes of these patients r...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2024-12-01
|
| Series: | Journal of Ophthalmic & Vision Research |
| Subjects: | |
| Online Access: | https://knepublishing.com/index.php/JOVR/article/view/14578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Purpose: To assess the efficiency and safety of pilocarpine eye drop 1.25% analogue (IRPilo) in comparison with its original brand-name drug (Vuity).
Methods: In this non-randomized comparative study, 75 patients with presbyopia aged 40 to 60 years were enrolled. The right eyes of these patients received either IR-Pilo (n = 45) or Vuity (n = 30) and their contralateral eyes served as controls. Refractive errors, distance best-corrected visual acuity (BCVA), near vision, amplitude of accommodation, pupil size, and intraocular pressure (IOP) were measured before and 1 to 2 hours after instillation of the eye drop.
Results: The mean refractive error was stable, except for a small myopic shift in the Vuity group. There was no significant change in distance BCVA. Near vision improved significantly in both intervention groups (P < 0.001) with preference for IR-Pilo (4 vs 2.3). Furthermore, a higher amplitude of accommodation and pupil constriction occurred after instillation of both drops, with a higher effect associated with IR-Pilo. However, IOP did not change significantly post intervention.
Conclusion: IR-Pilo and Vuity eye drops had comparable results; both were effective and led to stable distance vision and improved near vision. Both ophthalmic drugs were safe and none of them were associated with significant adverse effects.
|
|---|---|
| ISSN: | 2008-2010 2008-322X |